Sales of Lilly’s incretin medicines, Mounjaro, Trulicity and Zepbound, missed estimates, while that of non-incretin drugs like Jardiance, Taltz and Verzenio beat expectations. Lilly’s non ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

That’s why one of the most closely watched elements of a company’s earnings report is the guidance it gives for the next quarter or year. We’re still midway through the current earnings season, but ...

Trulicity sales were $5.46 billion in the first nine months of 2023 - a slight decline on the same period of 2022 that Lilly said was down to shortages, as well as increased competition in the market.